Harald Fricke
Director Técnico/Científico/I+D en Apogenix AG .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Peter Heinrich Krammer | M | 58 |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | 19 años |
| Friedrich von Bohlen und Halbach | M | 61 |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | - |
| Henning Walczak | M | - |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | 19 años |
| Hartmut Voss | M | - |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | - |
| Thomas Höger | M | - |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | 19 años |
| Mathias Hothum | M | 58 |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | - |
| Josef Puchta | M | 70 |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Holger Jürgensen | M | 67 |
RWTH Aachen University
| 9 años |
| Eckhard Geulen | M | - |
RWTH Aachen University
| 12 años |
| Frank Boshoff | M | 58 |
RWTH Aachen University
| 6 años |
| Peter Klingenberger | M | 67 |
RWTH Aachen University
| 8 años |
| Martin Komischke | M | 67 |
RWTH Aachen University
| 11 años |
| Wolfgang Nickels | M | 67 |
RWTH Aachen University
| 11 años |
| Wolfgang Söhngen | M | - |
RWTH Aachen University
| 5 años |
| Peter M. Herzig | M | 69 |
RWTH Aachen University
| 7 años |
| Gerd Schubert | M | 64 |
RWTH Aachen University
| 8 años |
| Clemens Miller | M | 65 |
RWTH Aachen University
| - |
| Hans-Joachim Konz | M | 64 |
RWTH Aachen University
| 5 años |
| Mansour Khatib | M | 61 |
RWTH Aachen University
| 4 años |
| Si-Young Jung | M | 65 |
RWTH Aachen University
| 4 años |
| Bernd Boisten | M | - |
RWTH Aachen University
| 4 años |
| Dirk Erich Mausbeck | M | 61 |
RWTH Aachen University
| 5 años |
| Peter Feld | M | 59 |
RWTH Aachen University
| 5 años |
| Bertram Stausberg | M | 58 |
RWTH Aachen University
| 4 años |
| Klaus K. Wilgenbus | M | 62 |
RWTH Aachen University
| 3 años |
| Goetz Kalckreuth | M | - |
RWTH Aachen University
| 1 años |
| Marcus Bollig | M | 57 |
RWTH Aachen University
| 6 años |
| Ping He | M | 67 |
RWTH Aachen University
| 3 años |
| Ahmet Fahri Yigitbasi | M | 66 |
RWTH Aachen University
| 4 años |
| Hubert Fink | M | 62 |
RWTH Aachen University
| 3 años |
| Dag Hagby | M | 64 |
RWTH Aachen University
| 5 años |
| Egon Renfordt-Sasse | M | 67 |
RWTH Aachen University
| 4 años |
| Jürgen Vutz | M | 67 |
RWTH Aachen University
| 3 años |
| Ursula Gather | M | 71 |
RWTH Aachen University
| 9 años |
| Klaus Fröhlich | M | 64 |
RWTH Aachen University
| 4 años |
| Roland Harings | M | 61 |
RWTH Aachen University
| 4 años |
| Christoph von Plotho | M | 68 |
RWTH Aachen University
| 3 años |
| Alexander Felix Tanudjaja | M | 68 |
RWTH Aachen University
| 4 años |
| Gerd Auffarth | M | 59 |
RWTH Aachen University
| 3 años |
| Jin Wu Xu | M | 75 |
RWTH Aachen University
| 3 años |
| Mathias Lütgendorf | M | - |
RWTH Aachen University
| 3 años |
| Norbert Schürmann | M | 63 |
RWTH Aachen University
| 6 años |
| Peter Schrimpf | M | 67 |
RWTH Aachen University
| 6 años |
| Johannes Meier | M | 61 |
RWTH Aachen University
| 5 años |
| Heinz Konrad Junker | M | 74 |
RWTH Aachen University
| 3 años |
| Udo Ungeheuer | M | 73 |
RWTH Aachen University
| 3 años |
| Karl-Peter Merz | M | 67 |
RWTH Aachen University
| 3 años |
| Rolf Breidenbach | M | 61 |
RWTH Aachen University
| 1 años |
| Rolf Buch | M | 59 |
RWTH Aachen University
| 4 años |
| Helmut Leube | M | 70 |
RWTH Aachen University
| 3 años |
| Ulrich H. R. Schumacher | M | 66 |
RWTH Aachen University
| 3 años |
| Rolf Martin Schmitz | M | 67 |
RWTH Aachen University
| 6 años |
| Gerhard Fettweis | M | 62 |
RWTH Aachen University
| 3 años |
| Christian Schäfer | M | - |
RWTH Aachen University
| 3 años |
| Georg Weyer | M | 67 |
RWTH Aachen University
| 3 años |
| Edgar Josef Schnorpfeil | M | 59 |
RWTH Aachen University
| 4 años |
| Willi Mannheims | M | 64 |
RWTH Aachen University
| 6 años |
| Hans-Josef Zimmer | M | 66 |
RWTH Aachen University
| 8 años |
| Andreas Radmacher | M | 59 |
RWTH Aachen University
| 4 años |
| Peter Ottenbruch | M | 66 |
RWTH Aachen University
| 3 años |
| Manfred Duernholz | M | 69 |
RWTH Aachen University
| 3 años |
| Kristian Schleede | M | 66 |
RWTH Aachen University
| 3 años |
| Andrea Böhmert | F | - |
RWTH Aachen University
| 7 años |
| Oliver Schlüter | M | - |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | - |
| Tian Jun Yang | M | 80 |
RWTH Aachen University
| 3 años |
| Ulrich Hüwels | M | 59 |
RWTH Aachen University
| 5 años |
| Khaled Ismail | M | - |
RWTH Aachen University
| - |
| Franz Richter | M | 68 |
RWTH Aachen University
| 3 años |
| Nowack Ralf | M | - |
RWTH Aachen University
| 8 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Alemania | 69 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Harald Fricke
- Red Personal
